Mother's Milk Study
To better understand the effects of breastfeeding on infant growth and development.
To better understand the effects of breastfeeding on infant growth and development.
The collection of the research data we hope will help better screening, diagnosing procedures and treatment of brain injury in newborns and identify a connection between MR imaging and neurodevelopmental outcomes.
Body Composition in Newborns with MRI of Congenital Adrenal Hyperplasia (CAH).
Develop non-invasive measures to identify abnormal placental function in babies with and without congenital anomalies.
Data Collection only. By reviewing the charts of CAH infants who come to our facility for treatment, we hope to discover which treatments, all of which are standard of care, lead to better outcomes for patients (primarily in the first year of life).
We are conducting a research study about visual problems in children with Autism Spectrum Disorder (ASD). We believe that many children with autism may have undiagnosed eye problems because they cannot explain when they have trouble seeing and may not undergo routine eye exams. We hope to develop a method to screen for visual problems in using a new, non-invasive technology called eye tracking. We will use a camera to record your child’s eye movements as they watch video clips for 15-20 minutes.
This research is being done to test the safety and effectiveness of intranasal carbetocin to treat Prader Willi Syndrome.
This study examines the relationship between social and nonsocial reward responsiveness and depression symptoms in adolescents (14-17 years old) with confirmed or suspected autism. Over time, we hope to understand mental health outcomes in teens (ages 14-17) with confirmed or suspected autism.
Over a 6-month period, adolescents and their parents will participate in clinical interviews, EEG tasks, and surveys about depression, mental health, and friendships, among other topics. Over time, we hope to understand depression and mental health outcomes in autistic adolescents with intellectual disability (14-17 years old) and their parents.
To explore the safety and treatment effect of intravenous (IV) Remodulin as add on therapy in neonates with PPHN compared to placebo.